Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light.

HIF prolyl hydroxylase 2 (PHD2) inhibitors represent a novel approach for treating HIF-related diseases. This study reports the first application of photoremovable protecting group to the photoactivatable inhibitor (7) of PHD2. It allows the inhibitory activity for PHD2 to be controlled by light irradiation, subsequently stabilizing HIF and promoting expression of the target gene. Light activation to stabilize HIF offers promising potentials for the tissue-specific therapies for HIF-related disease by light irradiation onto target tissues.

[1]  U. Holzgrabe,et al.  Fluorination of Photoswitchable Muscarinic Agonists Tunes Receptor Pharmacology and Photochromic Properties. , 2019, Journal of medicinal chemistry.

[2]  Q. You,et al.  Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors. , 2015, ACS medicinal chemistry letters.

[3]  A. Massaguer,et al.  A Green Light-Triggerable RGD Peptide for Photocontrolled Targeted Drug Delivery: Synthesis and Photolysis Studies. , 2016, The Journal of organic chemistry.

[4]  J. O'connor,et al.  Prolyl hydroxylase domain inhibitors: can multiple mechanisms be an opportunity for ischemic stroke? , 2019, Neuropharmacology.

[5]  G. Semenza,et al.  Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. , 1999, Annual review of cell and developmental biology.

[6]  H. Eichler,et al.  Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. , 2000, Blood.

[7]  J. Zondlo,et al.  Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Mukul R Jain,et al.  Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. , 2018, Journal of medicinal chemistry.

[9]  Gooitzen M van Dam,et al.  Emerging Targets in Photopharmacology. , 2016, Angewandte Chemie.

[10]  M. Famulok,et al.  Temporal and Reversible Control of a DNAzyme by Orthogonal Photoswitching. , 2018, Journal of the American Chemical Society.

[11]  Wiktor Szymanski,et al.  Photoactivation of MDM2 Inhibitors: Controlling Protein–Protein Interaction with Light , 2018, Journal of the American Chemical Society.

[12]  P. Toselli,et al.  Hypoxia-response element (HRE)-directed transcriptional regulation of the rat lysyl oxidase gene in response to cobalt and cadmium. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  D. Trauner,et al.  A roadmap to success in photopharmacology. , 2015, Accounts of Chemical Research.

[14]  P. Ratcliffe,et al.  Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. , 2013, ACS chemical biology.

[15]  Jing Gu,et al.  Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia. , 2018, Journal of medicinal chemistry.

[16]  B. Feringa,et al.  Orthogonal control of antibacterial activity with light. , 2014, ACS chemical biology.

[17]  S. Walmsley,et al.  Inflammation and Hypoxia: HIF and PHD Isoform Selectivity. , 2019, Trends in molecular medicine.

[18]  M. Ivan,et al.  Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling , 2002, Science.

[19]  J. Hale,et al.  Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia , 2010, Expert opinion on therapeutic patents.

[20]  Verónica San Miguel,et al.  Wavelength-selective caged surfaces: how many functional levels are possible? , 2011, Journal of the American Chemical Society.

[21]  R. Givens,et al.  Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy , 2012, Chemical reviews.

[22]  Ting-Ting Wu,et al.  Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson’s Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function , 2018, Front. Aging Neurosci..

[23]  M. Weiss,et al.  Anemia: progress in molecular mechanisms and therapies , 2015, Nature Medicine.